Cyclo TherapeuticsCYTH
Market Cap: $19.6M
About: Cyclo Therapeutics Inc is a clinical-stage biotechnology firm. The company is engaged in developing cyclodextrin-based products for treating neurodegenerative diseases, particularly Niemann-Pick Type C disease (NPC). The company's lead drug candidate, Trappsol Cyclo, has undergone clinical trials for NPC treatment. Operating in one segment, the company focuses on developing and commercializing cyclodextrin-based treatments for rare diseases. Revenue primarily comes from selling cyclodextrins and related products to pharmaceutical and nutritional industries, with Trappsol HPB and Trappsol Fine Chemical being significant contributors.
Employees: 8
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
5% more funds holding
Funds holding: 21 [Q1] → 22 (+1) [Q2]
0.28% more ownership
Funds ownership: 7.54% [Q1] → 7.82% (+0.28%) [Q2]
0% more funds holding in top 10
Funds holding in top 10: 2 [Q1] → 2 (+0) [Q2]
6% less capital invested
Capital invested by funds: $3.01M [Q1] → $2.84M (-$168K) [Q2]
17% less repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 6
Research analyst outlook
3 Wall Street Analysts provided 1 year price targets over the past 3 months
3 analyst ratings
Ascendiant Capital Lucas Ward 25% 1-year accuracy 2 / 8 met price target | 39%upside $0.95 | Buy Maintained | 26 Aug 2024 |
HC Wainwright & Co. Swayampakula Ramakanth 31% 1-year accuracy 43 / 137 met price target | 39%upside $0.95 | Neutral Downgraded | 23 Aug 2024 |
HC Wainwright & Co. Swayampakula Ramakanth 31% 1-year accuracy 43 / 137 met price target | 338%upside $3 | Buy Reiterated | 16 Aug 2024 |
Financial journalist opinion
Based on 7 articles about CYTH published over the past 30 days